Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma

被引:35
|
作者
Koh, Mei Yee [1 ]
Vuvi Nguyen [2 ]
Lemos, Robert, Jr. [1 ]
Darnay, Bryant G. [2 ]
Kiriakova, Galina [2 ]
Abdelmelek, Mena [2 ]
Ho, Thai H. [3 ]
Karam, Jose [4 ]
Monzon, Federico A. [5 ]
Jonasch, Eric [4 ]
Powis, Garth [1 ]
机构
[1] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[3] Mayo Clin Arizona, Dept Hematol Oncol, Scottsdale, AZ USA
[4] Univ Texas MD Anderson Canc Ctr, Dept GU Med Oncol, Houston, TX 77030 USA
[5] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
关键词
INDUCIBLE FACTOR; TUMOR-SUPPRESSOR; VHL LOSS; GENE; EXPRESSION; CANCER; ERYTHROPOIETIN; HIF-2-ALPHA; HIF1-ALPHA; OCT-4;
D O I
10.1158/0008-5472.CAN-13-2190
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role, HIF2 plays a distinct role in driving CRCC. In this study, we show that the HIF1 alpha E3 ligase hypoxia-associated factor (HAF) complexes with HIF2 alpha at DNA to promote HIF2-dependent transcription through a mechanism relying upon HAF SUMOylation. HAF SUMOylation was induced by hypoxia, whereas HAF-mediated HIF1 alpha degradation was SUMOylation independent. HAF overexpression in mice increased CRCC growth and metastasis. Clinically, HAF overexpression was associated with poor prognosis. Taken together, our results show that HAF is a specific mediator of HIF2 activation that is critical for CRCC development and morbidity. (C) 2014 AACR.
引用
收藏
页码:316 / 329
页数:14
相关论文
共 50 条
  • [1] Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
    Ricketts, Christopher J.
    Crooks, Daniel R.
    Linehan, W. Marston
    CANCER CELL, 2016, 30 (04) : 515 - 517
  • [2] Targeting HIF2 in Clear Cell Renal Cell Carcinoma
    Cho, Hyejin
    Kaelin, William G.
    TARGETING CANCER, VOL 81, 2016, 2016, 81 : 113 - 121
  • [3] The role of the E3 ubiquitin ligase Parkin in clear cell renal cell carcinoma
    Esser, Laura Kristin
    Branchi, Vittorio
    Shaker, Farhad
    Simon, Adrian Georg
    Stephan, Carsten
    Kristiansen, Glen
    Buness, Andreas
    Schorle, Hubert
    Toma, Marieta I.
    CANCER RESEARCH, 2022, 82 (12)
  • [4] HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma
    Qiu, Bo
    Ackerman, Daniel
    Sanchez, Danielle J.
    Li, Bo
    Ochocki, Joshua D.
    Grazioli, Alison
    Bobrovnikova-Marjon, Ekaterina
    Diehl, J. Alan
    Keith, Brian
    Simon, M. Celeste
    CANCER DISCOVERY, 2015, 5 (06) : 652 - 667
  • [5] Targeting HIF2α with an RNAi therapeutic for the treatment of clear cell renal cell carcinoma
    Nicholas, A.
    Wong, S.
    Zhu, R.
    Carlson, J.
    Frankiewicz, A.
    Shu, D.
    Hamilton, H.
    Schienebeck, C.
    Andersen, A.
    Fowler-Watters, M.
    Bertin, S.
    Liu, C.
    Li, X.
    Chen, B.
    Schumacher, J.
    Hegge, J.
    Given, B.
    Li, Z.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E9 - E9
  • [6] HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma
    Wong, So C.
    Cheng, Weijun
    Hamilton, Holly
    Nicholas, Anthony L.
    Wakefield, Darren H.
    Almeida, Aaron
    Blokhin, Andrei V.
    Carlson, Jeffrey
    Neal, Zane C.
    Subbotin, Vladimir
    Zhang, Guofeng
    Hegge, Julia
    Bertin, Stephanie
    Trubetskoy, Vladimir S.
    Rozema, David B.
    Lewis, David L.
    Kanner, Steven B.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 140 - 149
  • [7] FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma
    Yang D.
    Li Q.
    Lu P.
    Wu D.
    Li W.
    Meng X.
    Xing M.
    Shangguan W.
    Chen B.
    Yang J.
    Zhang Z.
    Wang Z.
    Huang D.C.S.
    Zhao Q.
    Journal of Biological Chemistry, 2024, 300 (01)
  • [8] Effects of HIF-1 alpha and HIF2 alpha on Growth andMetabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts
    Biswas, Swethajit
    Troy, Helen
    Leek, Russell
    Chung, Yuen-Li
    Li, Ji-liang
    Raval, Raju R.
    Turley, Helen
    Gatter, Kevin
    Pezzella, Francesco
    Griffiths, John R.
    Stubbs, Marion
    Harris, Adrian L.
    JOURNAL OF ONCOLOGY, 2010, 2010
  • [9] FLCN Regulates HIF2α Nuclear Import and Proliferation of Clear Cell Renal Cell Carcinoma
    Zhao, Xuyang
    Ma, Yadong
    Cui, Jie
    Zhao, Haiyang
    Liu, Lei
    Wang, Yueyuan
    Min, Pengxiang
    Zhang, Lin
    Chen, Yongchang
    Du, Jun
    Zhang, Yujie
    Gu, Luo
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [10] Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
    Rioja, Patricia
    Rey-Cardenas, M.
    De Velasco, Guillermo
    CANCER TREATMENT REVIEWS, 2024, 129